$0The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.
$0.00 - $0.00The lowest and highst price in the last 52 weeks.
0.0xThe price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.
$0.00 (0.0%)Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).
|Dividend Yield||$0.00 (0.0%)|
|1 Year Return||0.0%|
|Outstanding Shares||105 Million|
|Avg 30 Day Volume||0|
|Earnings per Share||$0.00|
|Price to Sales Ratio||-|
|Price to Book Ratio||-|
|Revenue to Enterprise Value||-|
|EBIT to Enterprise Value||-|
|Total Debt to Enterprise Value||-|
|Debt to Equity||-|
|Quarterly Earnings Growth (YoY)||-|
|Return on Equity||-|
|Return on Assets||-|
|Return on Invested Capital||-|
20,487 shares sold (3 transactions)
23,802 shares sold (1 transactions)
3,646 shares sold (1 transactions)
Industry: Biological Product (except Diagnostic) Manufacturing
Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s two clinical programs, TTI-621 and TTI-622, target CD47, a “don’t eat me” signal that cancer cells frequently use to evade the immune system.
No summary available.Seeking Alpha, 20 days ago
No summary available.Seeking Alpha, 21 days ago
Trillium Therapeutics Inc. (TSE:TRIL) shares were up 0.1% during trading on Monday . The stock traded as high as C$22.48 and last traded at C$22.47. Approxim...Transcript Daily, 21 days ago
Integral Health Asset Management LLC acquired a new position in Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR) during the 2nd quarter, according to its mo...Dakota Financial News, 26 days ago